Talecris Biotherapeutics Holdings Corp. - Momentum
18 Avril 2011 - 2:00AM
Zacks
Talecris Biotherapeutics Holdings Corp. (TLCR) recently hit
a new all-time high after spending the last six months advancing
along a very steady trend line. With an average earnings surprise
of 9% over the last four quarters and estimates on the upswing,
this Zacks #1 rank stock provides the right remedy for momentum.
Company Description
Telacris Bio therapeutics Holding Corp. is a
biopharmaceutical company that specializes in the development of
plasma-derived protein therapies worldwide with a market cap of
$3.56 billion.
Our last major update on TLCR's business came in
late February when the company reported strong Q4 results that
included sharp gains from last year.
Fourth-Quarter Results
Revenue for the period was up 5% from last year to
$411 million. Net looked even better, spiking to $17 million from
$1.4 million last year.
The strong results were driven by solid gains in
Gamunex-C/Gamunex IGIV revenue, which was up 10% from last year to
$21 million.
Margin expansion also helped the cause, with gross
margin climbing to 41.2% from 39.2% last year.
Financial Profile
The company has also been very focused on
strengthening its balance sheet, with cash and equivalents jumping
$133 million to $198 million against long-term debt and capital
lease obligations of $605 million.
Estimates
We saw some movement in estimates off the good
quarter, with the current year up 7 cents in the last two months to
$1.81 while the next-year estimate gained 8 cents in the same time
to $1.93, a solid 7% growth projection.
Valuation
But in spite of the solid gains, the valuation
picture still looks solid, with a forward P/E of 15.5X, a decent
discount to its peer average of 17X.
6-Month Chart
On the chart, shares recently surged into a new
all-time high after trending higher for most of the last six
months. Look for support from the trend line on any weakness, take
a look below.
Michael Vodicka is the Momentum Stock Strategist
for Zacks.com. He is also the Editor in charge of the Zacks
Momentum Trader Service.
TALECRIS BIOTHR (TLCR): Free Stock Analysis Report
Zacks Investment Research
Talecris Biotherapeutics Holdings Corp. (MM) (NASDAQ:TLCR)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Talecris Biotherapeutics Holdings Corp. (MM) (NASDAQ:TLCR)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024